Discover a study on PARP inhibitors in prostate cancer, revealing survival benefits for patients with BRCA1/2 alterations.
Hosted on MSN
Stopping DNA damage in T cells during PARP inhibitor cancer treatment enhances antitumor effectiveness
The cancer drugs called PARP inhibitors have a puzzling reputation: even though they are treatment mainstays for multiple forms of cancer, they can damage cancer-killing T cells and disrupt the ...
Olaparib is the only PARP inhibitor that significantly improves overall survival in PSROC, distinguishing it from other PARP inhibitors. All four PARP inhibitors enhance progression-free survival, ...
Most recurrent ovarian cancer cases arise in patients previously treated with PARP inhibitors making these results noteworthy ...
Niraparib combined with abiraterone acetate and prednisone improved rPFS in mCSPC patients with HRR gene alterations, especially BRCA1/2 mutations. The combination showed potential in reducing ...
Poly(ADP-ribose) polymerase (PARP) inhibitors should be considered a treatment option for patients with uterine leiomyosarcomas harboring BRCA2 deep deletions, researchers advised. PARP inhibitors are ...
Man patient speaking talking doctor receiving chemotherapy treatment iv infusion Platinum chemotherapy is a valid treatment option in patients with BRCA mutations, according to investigators. Poly ADP ...
Poly adenosine diphosphate-ribose polymerase inhibitors, an important class of anticancer drugs, employ synthetic lethality strategy and are particularly effective against cancers with genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback